- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Agilent Technologies Inc(A)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for A
11/19/2026: A (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Agilent Technologies Inc is a prominent global life sciences and analytical instrumentation company that provides specialized laboratory equipment, software, and services. The company's primary strengths lie in its massive installed base of chromatography systems and high-margin recurring CrossLab services, which foster dependable financial resilience. Its main growth opportunity centers on expanding biopharma workflows, cell analysis, and nucleic acid therapeutics manufacturing. Key risks include exposure to cyclical biopharma spending slowdowns and intense competition from larger industry peers like Thermo Fisher Scientific. The stock suits long-term investors seeking stable exposure to healthcare and laboratory tools, with a need to monitor biopharmaceutical R&D spending trends and acquisition execution.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Agilent delivers steady mid-single-digit organic growth with upside from biopharma and genomics, but lacks high-beta hyper-growth. |
| Momentum investor | Strong fit while signal remains positive | Conditional on a positive technical upturn signal, Agilent can experience sustained upward momentum driven by biopharma spending recovery. |
| Value investor | Mixed fit | The stock trades at premium valuation multiples typical of high-quality life science franchises, limiting deep-value bargains. |
| Dividend investor | Mixed fit | Agilent pays a reliable and growing dividend, but its lower starting dividend yield appeals more to total-return than income-focused investors. |
| Low-risk investor | Strong fit | Solid balance sheet strength, high recurring revenues, and defensive healthcare/laboratory exposure make it relatively stable. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | The stock experiences moderate fluctuations tied to broader market sentiment and quarterly biopharma capital spending updates. |
| Valuation risk | Medium / high | Trading at elevated price-to-earnings multiples leaves the stock sensitive to any sudden growth deceleration. |
| Competition risk (Thermo Fisher and Danaher) | High | Agilent competes against larger, highly diversified life science giants that can bundle instruments and consumables aggressively. |
| Business quality | Strong | Agilent features a high-quality business model underpinned by proprietary technology, high switching costs, and strong recurring service revenue. |
| Dividend income | Low | Modest dividend yields mean the company is not structured primarily for immediate income generation. |
| Execution risk | Medium | Successfully integrating recent acquisitions like BIOVECTRA and scaling new manufacturing operations execution remains critical. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 50.00B USD | Price to earnings Ratio 34.98 | 1Y Target Price 183.14 |
Price to earnings Ratio 34.98 | 1Y Target Price 183.14 | ||
Volume (30-day avg) 2.0M shares | Beta 1.24 | 52 Weeks Range 107.98 - 182.99 | Updated Date 11/18/2026 |
52 Weeks Range 107.98 - 182.99 | Updated Date 11/18/2026 | ||
Dividends yield (FY) 0.59% | Basic EPS (TTM) 5.07 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 61.0%
- Active BUY / eligible
- 64 / 105
- 30-Day BUY Count Change
- +16
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Diagnostics & Research
- BUY participation
- 42.9%
- Active BUY / eligible
- 6 / 14
- 30-Day BUY Count Change
- -3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 16.45% | Avg. Invested days 51 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Life Sciences and Applied Markets Group (LSAG) | Sale of liquid and gas chromatography systems, mass spectrometers, spectroscopy instruments, and cell analysis tools. | This is the core equipment engine that places hardware instruments into labs globally. |
| Agilent CrossLab Group (ACG) | Recurring revenue from laboratory services, maintenance contracts, software licenses, training, and chemical consumable supplies. | Provides a predictable, high-margin stream of recurring revenue that buffers against hardware cycle swings. |
| Diagnostics and Genomics Group (DGG) | Reagents for cancer pathology (Dako), nucleic acid therapeutics manufacturing, and genomic research tools. | Captures high-value clinical diagnostic and precision medicine revenue streams. |
| Geographic Exposure | Global sales spanning the Americas, Europe, and Asia-Pacific (including significant volume in China). | International diversification provides broad market reach but exposes earnings to regional macroeconomic and currency shifts. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-23 | When After Market | Estimate 1.72 | Actual - |
Profitability
Profit Margin 19.53% | Operating Margin (TTM) 24.54% |
Management Effectiveness
Return on Assets (TTM) 8.63% | Return on Equity (TTM) 20.97% |
Valuation
Trailing PE 34.98 | Forward PE 25.51 | Enterprise Value 50.74B | Price to Sales(TTM) 6.78 |
Enterprise Value 50.74B | Price to Sales(TTM) 6.78 | ||
Enterprise Value to Revenue 6.88 | Enterprise Value to EBITDA 24.94 | Shares Outstanding 281.97M | Shares Floating 281.23M |
Shares Outstanding 281.97M | Shares Floating 281.23M | ||
Percent Insiders 0.21 | Percent Institutions 95.37 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

